Journal of Cancer Therapy
Vol.7 No.9(2016), Paper ID 70276, 13
pages
DOI:10.4236/jct.2016.79065
Excision Repair Cross-Complementation Group 1 (ERCC1): A Prognostic and Predictive Biomarker in Patients with Colorectal Cancer Receiving Adjuvant Oxaliplatin Based Chemotherapy
Adel Gabr, T. M. Elsaba, Khalid Razek, Shaima Tamam, Haisam Atta
Department of Medical Oncology, South Egypt Cancer Institute, Assuit University, Assiut, Egypt
Department of Pathology, South Egypt Cancer Institute, Assuit University, Assiut, Egypt
Department of Surgical Oncology, South Egypt Cancer Institute, Assuit University, Assiut, Egypt
Department of Radiotherapy, South Egypt Cancer Institute, Assuit University, Assiut, Egypt
Department of Diagnostic Radiology, South Egypt Cancer Institute, Assuit University, Assiut, Egypt
Copyright © 2016 Adel Gabr, T. M. Elsaba, Khalid Razek, Shaima Tamam, Haisam Atta et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Gabr, A. , Elsaba, T. , Razek, K. , Tamam, S. and Atta, H. (2016) Excision Repair Cross-Complementation Group 1 (ERCC1): A Prognostic and Predictive Biomarker in Patients with Colorectal Cancer Receiving Adjuvant Oxaliplatin Based Chemotherapy.
Journal of Cancer Therapy,
7, 622-634. doi:
10.4236/jct.2016.79065.